Moderna jumps on personalized mRNA Phase 3 success; raises $2.96B via 0% notes

Moderna surged on Phase 3 success for a personalized mRNA cancer vaccine with Keytruda in resected stage IIB–IV melanoma. The company also raised about $2.96B through 0% convertible notes due 2032 with capped calls.